Equities

abrdn Life Sciences Investors

HQL:NYQ

abrdn Life Sciences Investors

Actions
FinancialsClosed End Investments
  • Price (USD)12.98
  • Today's Change-0.035 / -0.27%
  • Shares traded162.53k
  • 1 Year change-7.52%
  • Beta0.7240
Data delayed at least 15 minutes, as of Apr 15 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.

  • Revenue in USD (TTM)3.50m
  • Net income in USD22.35m
  • Incorporated1992
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inflection Point Acquisition Corp II0.006.75m328.44m--50.241.33----0.20920.20920.007.87----------------------------0.00--------------
Nuveen New York Quality Muncpl Incm Fund-100.00bn-100.00bn328.57m--------------------------------------------------------------
RiverNorth Flexible Mncpl Inm Fnd II Inc25.31m23.99m329.72m--13.740.878--13.030.98530.98531.0415.420.0407--7.37--3.85--3.90--29.83--94.80------0.3891--20.12--116.72------
Putnam Premier Income Trust25.13m18.03m331.41m0.0018.290.8884--13.190.18730.18730.26223.860.0298--0.2493--2.14-0.07713.40-0.110187.8385.7671.73-2.64--6.220.00--1.28-7.53104.67-51.59--0.1287
John Hancock Preferred Income Fund II-100.00bn-100.00bn334.35m--------------------------------------------------------------
Net Lease Office Properties174.97m-131.75m334.88m----0.4892--1.91-8.98-8.9811.9646.30----------------78.37---75.28----0.94030.443--12.00---934.95------
Grayscale Digital Large Cap Fund LLC0.00215.03m335.99m--1.560.8989----13.5513.550.0023.560.00------80.76--80.76--------------0.00------150.82------
Duff & Phelps Utlty and Infrstct Fnd Inc16.64m-38.40m337.72m----0.8904--20.29-1.01-1.010.43599.930.0276--9.64---6.381.57-6.411.57-7.1522.50-230.7458.59---0.04230.2966455.99-4.24-8.38-204.11-----2.09
Abrdn Life Sciences Investors3.50m22.35m340.10m--14.890.8649--97.210.87120.87120.130615.000.0086--1.23--5.471.545.591.56-35.89-68.31638.85238.14----0.00514.0115.8911.99121.37-4.85----
Source Capital Inc19.56m53.64m340.12m0.006.310.9389--17.396.536.532.3843.910.0559--6.16--15.318.3915.438.5285.1977.71274.21242.66----0.0066.8249.0918.97298.03----20.76
Tortoise Energy Infrastructure Corp15.76m-15.62m341.31m----1.13--21.66-1.04-1.041.4626.550.0282--8.27---2.80-11.75-2.89-12.0056.4734.53-99.13-751.85--0.23680.2206--20.10---115.13-----22.98
abrdn Income Credit Strategies Fund-100.00bn-100.00bn342.88m--------------------------------------------------------------
Eaton Vance Floating-Rate Income Trust-100.00bn-100.00bn345.59m0.00------------------------------------------------------------
KKR Income Opportunities Fund53.06m53.84m351.21m--4.890.7694--6.622.652.652.6116.830.1076--3.42--10.922.7611.072.8477.6479.12101.4732.75----0.3122212.9538.755.14186.7813.36---1.37
Data as of Apr 15 2024. Currency figures normalised to abrdn Life Sciences Investors's reporting currency: US Dollar USD

Institutional shareholders

21.93%Per cent of shares held by top holders
HolderShares% Held
Saba Capital Management LPas of 05 Feb 20242.21m8.45%
Cornerstone Advisors LLC (North Carolina)as of 31 Dec 2023494.34k1.89%
1607 Capital Partners LLCas of 31 Dec 2023480.18k1.83%
Allspring Global Investments LLCas of 31 Dec 2023454.15k1.73%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023430.27k1.64%
AQR Arbitrage LLCas of 31 Dec 2023384.23k1.47%
Clough Capital Partners LPas of 31 Dec 2023375.41k1.43%
RPO LLCas of 31 Dec 2023338.54k1.29%
Needham Investment Management LLCas of 31 Dec 2023313.79k1.20%
Flagship Harbor Advisors LLCas of 31 Dec 2023264.00k1.01%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.